Authors

Latest:

Dr. Pinato on PD-L1 Testing in HCC

David J. Pinato, MD, NIHR Academic Clinical Lecturer in Medical Oncology, resident, Royal Brompton Hospital and Imperial College London, discusses the role of PD-L1 testing in hepatocellular carcinoma.

David J. Pinato, MD, PhD

Latest:

Dr. Pinato on Guidelines for Toxicity Management in HCC

David J. Pinato, MD, discusses guidelines for toxicity management in hepatocellular carcinoma (HCC).

David J. Straus, MD

Latest:

Dr. Straus on the 3-Year Results of the ECHELON-1 Study in Hodgkin Lymphoma

David J. Straus, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the 3-year follow-up results of the ECHELON-1 study, which examines brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma.

David James Pinato, MD, MRCP, PhD

Latest:

HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.

David Korones, MD

Latest:

(Never) A Typical Day in the Life of a Pediatric Hematologist/Oncologist

There is no such thing as a typical day. Our days are punctuated by the unexpected and our field is so diverse that we often change what we do over the course of our careers. Time alters us and our field.

David L. Rimm, MD, PhD

David Rimm is the

Latest:

Dr Rimm on How FDA-Approved IHC Tests Pose Reproducibility Challenges in Breast Cancer

David Rimm, MD, PhD, discusses how FDA-approved IHC assays may lack reproducibility in real-world settings in breast cancer.

David Liu, MD, FSIR, University of British Columbia

David Lucas, PhD

Latest:

David Lucas Discusses the Bromodomain Inhibitor OTX015

David Lucas, PhD, assistant professor, division of hematology, Ohio State University, discusses the bromodomain inhibitor OTX015.

David M. Euhus, MD

Latest:

Dr. Euhus on the Rarity of Angiosarcoma of the Breast

David M. Euhus, MD, director of breast surgery, professor of surgery, Johns Hopkins Medicine, discusses the rarity of angiosarcoma of the breast.

David M. Gershenson, MD

Latest:

Dr. Gershenson on the Results of the MILO Trial in Low-Grade Serous Ovarian Cancer

David M. Gershenson, MD, discusses the results of the phase 3 MILO trial in low-grade serous ovarian cancer.

David M. Jackman

Latest:

Dr. Jackman on Benefits of Liquid Biopsies in Lung Cancer

David M. Jackman, MD, medical director of Clinical Pathways, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses the benefits of liquid biopsies for patients with lung cancer.

David M. Jackman, MD

Latest:

Dana-Farber Embraces Pathways in Clinical Practice

David M. Jackman, MD, the medical director of Clinical Pathways at Dana-Farber, discusses the benefits of a clinical pathways system.

David M. Jackman, MD, Dana-Farber Cancer Institute

David M. Kurtz, MD, PhD

Latest:

Dr. Kurtz Discusses Using ctDNA to Detect Lymphoma

David M. Kurtz, MD, PhD, instructor of medicine, Postdoctoral Fellow, Divisions of Oncology & Hematology, Stanford Cancer Center, Stanford University, discusses using circulating tumor DNA to detect lymphoma.

David M. Nanus, MD

Latest:

Dr. Nanus on Trials Investigating Immunotherapy in RCC

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses trials investigating immunotherapy regimens for patients with renal cell carcinoma (RCC).

David M. Schuster, MD

Latest:

Dr. Schuster on Detecting Bone Metastases in Breast Cancer

David Schuster, MD, director, from Emory University, compares the efficacy of bone scans and FDG-PET/CT scans for detecting bone metastases in patients with breast cancer.

David M. Siegel, MD, PhD

Latest:

Dr Siegel on the Current and Future Role of Mezigdomide in Multiple Myeloma

David Samuel Dicapua Siegel, MD, discusses the current and future role for mezigdomide in the multiple myeloma treatment paradigm.

David Maloney, MD, PhD

Latest:

Dr. Maloney on Targets for CAR T-Cell Therapy

David Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the success and challenges of chimeric antigen recptor (CAR) T-cell therapy in hematologic malignancies.

David Maloney, MD, PhD Fred Hutchinson Cancer Research Center

David Miklos, MD, Stanford University

Latest:

Use of CAR T-Cell Therapies in Earlier Lines of DLBCL

Panelists discuss data on the use of CAR T-cell therapies in earlier lines and implications of these data on the DLBCL treatment landscape going forward.